Altria Group, Inc.

Altria's Q1 2026 results demonstrated that strong pricing power continues to more than offset declining cigarette shipment volumes, with the smokeable products segment delivering margin expansion and EPS of $1.32, beating consensus estimates. Marlboro retained its premium segment leadership with a slight share increase of 0.1%.

Consensus analysts expect Altria's normalized EPS growth to decelerate sharply, from 7.3% in Q1 2026 to just 3% by early 2027. Rising living costs are pushing smokers toward cheaper alternatives, and the structural decline in smoking volumes raises serious doubts about how long pricing power alone can sustain earnings momentum.

Altria's reaffirmed 2026 EPS guidance of $5.56–$5.72, representing growth of 2.5%–5.5%, reflects management confidence in navigating the regulatory landscape. The company's entrenched Marlboro brand and loyal premium customer base provide a resilient foundation even amid evolving FDA oversight.

The FDA's May 2026 policy could rapidly authorize 100 to 200 additional vape products, intensifying competition against Altria's cigarette business. This regulatory shift threatens the cigarette volume stabilization that underpins Wall Street's EPS growth assumptions, potentially undermining the core investment thesis.

TIKR's valuation model targets Altria stock at $86 by December 2030, implying the stock is approximately 20% undervalued at current levels. Historical data from Financhill further supports this view, showing MO has risen in 40 of the past 54 years over a subsequent 52-week period, with an average 12-month gain of 13.4%.

Wall Street's consensus of 4 buys, 7 holds, 1 underperform, and 1 sell yields a mean 12-month price target of just $71, suggesting the stock is essentially fairly valued or slightly overpriced at current levels near $73. Barclays maintains a Sell rating with a $64 target, citing meaningful downside risk.